| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 500mg | 电议 |
Cell lines | MNK45 gastric cancer cell line |
Preparation method | Soluble in water, ethanol, chloroform, toluene, and benzene. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 0.05, 0.10, 0.25, and 0.50 mg/ml for 48 h |
Applications | Matrine showed a dose-dependent inhibition of the growth of MKN45 cells and the concentration needed for 50% inhibition of growth of MKN45 cells was 0.5 mg/ml. It was also found that after matrine treatment at 0.05, 0.1, 0.25, and 0.50 mg/ml, the IKKa, IjBa, IjBb, phospho-IjBa proteins levels in MKN45 cells were significantly higher than those in control cells. In addition, the p-ERK protein expression level in low dose matrine-treated MKN45 cells was significantly higher than that in high dose matrine-treated MKN45 cells. |
Animal models | Adult male BALB/c mice |
Dosage form | 25, 50 or 100 mg/kg, i.p. |
Application | Treatment with matrine could significantly reduce LPS-induced mouse death, the accumulative mortalities during 3 days in high dose of matrine (100 mg/kg) treatment groups (55%) was significantly lower than that in LPS groups (80%). However, no protection was observed when mice received matrine treatment at dose of 25 mg/kg and 50 mg/kg. Matrine treatment could also significantly improve the lung injury, such as pulmonary edema, infiltration of inflammatory cells in the lung tissues and alveoli, and alveolar damage. There was no obvious change in lung structure in control and matrine groups. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| 产品描述 | IC50 Value: 540 μg/ml (inhibit gastric cancer cell line MNK45, MTT) [1] Matrine is an alkaloid found in plants from the Sophora genus. It has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor and ?-receptor agonist. in vitro: MTT assay showed that the matrine was able to inhibit gastric cancer cell line MNK45 in a dose-dependent manner. The concentration required for 50% inhibition (IC50) was found to be 540 μg/ml. This anti-tumor function was achieved through modulation of the NF-κB, XIAP, CIAP, and p-ERK proteins expression in cell line MNK45. Matrine induces apoptosis of human NSCLC cells with anti-apoptotic factors inhibited and dependent on caspase activity. In addition, we found that matrine increases the phosphorylation of p38 but not its total protein, and inhibition of the p38 pathway with SB202190 partially prevents matrine-induced apoptosis. Furthermore, matrine generates reactive oxygen species (ROS) in a dose- and time-dependent manner, which is reversed by pretreatment with N-acetyl-L-cysteine (NAC) [2]. in vivo: Oral administration of matrine (200, 100 and 50 mg/kg) significantly attenuated isoproterenol-induced cardiac necrosis and left ventricular dysfunction [3]. high dose of matrine significantly reduced the mortality rate of mice with LPS administration. Treatment with matrine improved LPS-induced lung histopathologic changes, alleviated pulmonary edema and lung vascular leak, inhibited MPO and MDA activity,and reduced the production of inflammatory mediators including TNF-α, IL-6 and HMGB1 [4]. Toxicity: N/A Clinical trial: N/A |
m.cnreagent.com